MedTrace Logo

FearLess in NeuroOncology

NCT06989086 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2025-09-09

No results posted yet for this study

Summary

The overarching goal of this project is to assess the feasibility, acceptability, and appropriateness of recruitment methods, target population, and a waitlist design to finalize the protocol of FearLess in primary malignant brain tumor patients and caregivers

Conditions

  • Primary Malignant Brain Tumor
  • Glioblastoma (GBM)
  • Astrocytoma
  • Oligodendroglioma
  • Caregiver

Interventions

BEHAVIORAL

Fearless in Neuro-Oncology

FearLess is a newly developed, empirically-rooted, manualized psychological intervention consisting of an intake + 8 sessions delivered over a 12-week time period. It consists of weekly individual 60- to 90-minute virtual therapy sessions.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • National Brain Tumor Society

    collaborator UNKNOWN

  • Virginia Commonwealth University

    lead OTHER

Principal Investigators

  • Ashlee R Loughan, Ph.D · Virginia Commonwealth University

  • Sarah E Braun, Ph.D. · Virginia Commonwealth University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-24
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06989086 on ClinicalTrials.gov